Online inquiry

IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7852MR)

This product GTTS-WQ7852MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets RTN4 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001321859.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57142
UniProt ID Q9NQC3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7852MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ45MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ3544MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ12824MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ6379MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ11206MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ12500MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ11370MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ11047MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-128
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW